699855P
3D-(6-acyl) PHAD®
Manufacturer: Sigma Aldrich
CAS Number: 252042-59-4
Synonym(S): Monophosphoryl Hexa-acyl Lipid A, 3-Deacyl (Synthetic)
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 1 MG | 699855P-1-MG | In Stock | ₹ 30,028.55 |
| 5 MG | 699855P-5-MG | In Stock | ₹ 1,19,637.90 |
| 699855P-10MG | 699855P-699855P-10MG | In Stock | ₹ 2,25,333.20 |
| 699855P-25MG | 699855P-699855P-25MG | In Stock | ₹ 4,66,027.08 |
699855P - 1 MG
In Stock
Quantity
1
Base Price: ₹ 30,028.55
GST (18%): ₹ 5,405.139
Total Price: ₹ 35,433.689
Assay
>99% (HPLC)
form
powder
packaging
pkg of 1 × 1 mg (699855P-1mg)pkg of 1 × 10 mg (699855P-10MG)pkg of 1 × 10 mg (699855P-25MG)pkg of 1 × 5 mg (699855P-5mg)
manufacturer/tradename
Avanti Polar Lipids
application(s)
vaccine development
shipped in
dry ice
storage temp.
−20°C
SMILES string
O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
Related Products
Description
- General description: Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.
- Application: 3D-(6-acyl) PHAD® has been used: as a synthetic adjuvant in human papillomavirus (HPV) and virus-like particles (VLPs)-based HPV vaccine preparations[1]as a component of liposomes for immunizing mice with P. falciparum (Pfs25) malaria transmission-blocking vaccine antigen candidate[2]in liposome preparation for the generation of army liposome formulation (ALF) for human immunodeficiency (HIV) gp140 antigen immunization studies in mice[3]
- Packaging: 2 mL Amber Glass Crimp Cap Vial (699855P-1mg)
- Other Notes: For R&D use only. Not for drug, household, or other uses.
- Legal Information: PHAD is a registered trademark of Avanti Polar Lipids, Inc.
SAFETY INFORMATION
WGK
WGK 3
Flash Point(F)
No data available
Flash Point(C)
No data available
Compare Similar Items
Show Difference
Assay: >99% (HPLC)
form: powder
packaging: pkg of 1 × 1 mg (699855P-1mg)pkg of 1 × 10 mg (699855P-10MG)pkg of 1 × 10 mg (699855P-25MG)pkg of 1 × 5 mg (699855P-5mg)
manufacturer/tradename: Avanti Polar Lipids
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
Assay:
>99% (HPLC)
form:
powder
packaging:
pkg of 1 × 1 mg (699855P-1mg)pkg of 1 × 10 mg (699855P-10MG)pkg of 1 × 10 mg (699855P-25MG)pkg of 1 × 5 mg (699855P-5mg)
manufacturer/tradename:
Avanti Polar Lipids
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
Assay: ≥99% (TLC)
form: powder
packaging: pkg of 1 × 10 mg (699856P-10MG)pkg of 1 × 5 mg (699856P-5MG)
manufacturer/tradename: Avanti Polar Lipids
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: [Na+].[Na+].CCCCCCCCCCCC(=O)NC1[C@@H](OP([O-])([O-])=O)OC(CO)[C@@H](OC(=O)CCCCCCCCCCC)C1OC(=O)CCCCCCCCCCC
Assay:
≥99% (TLC)
form:
powder
packaging:
pkg of 1 × 10 mg (699856P-10MG)pkg of 1 × 5 mg (699856P-5MG)
manufacturer/tradename:
Avanti Polar Lipids
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
[Na+].[Na+].CCCCCCCCCCCC(=O)NC1[C@@H](OP([O-])([O-])=O)OC(CO)[C@@H](OC(=O)CCCCCCCCCCC)C1OC(=O)CCCCCCCCCCC
Assay: ≥99% (TLC)
form: powder
packaging: pkg of 1 × 10 mg (699857P-10MG)pkg of 1 × 5 mg (699857P-5MG)
manufacturer/tradename: Avanti Polar Lipids
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: [Na+].CCCCCCCCCCCC(=O)NC1C(OC(=O)CCCCCCCCCCC)OC(CO)C(OP(O)([O-])=O)C1OC(=O)CCCCCCCCCCC
Assay:
≥99% (TLC)
form:
powder
packaging:
pkg of 1 × 10 mg (699857P-10MG)pkg of 1 × 5 mg (699857P-5MG)
manufacturer/tradename:
Avanti Polar Lipids
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
[Na+].CCCCCCCCCCCC(=O)NC1C(OC(=O)CCCCCCCCCCC)OC(CO)C(OP(O)([O-])=O)C1OC(=O)CCCCCCCCCCC
Assay: 96%
form: solid
packaging: __
manufacturer/tradename: __
application(s): __
shipped in: __
storage temp.: __
SMILES string: CC(C)(C)S(=O)N[C@@H]1CCCC[C@H]1NC(=O)Nc2cc(cc(c2)C(F)(F)F)C(F)(F)F
Assay:
96%
form:
solid
packaging:
__
manufacturer/tradename:
__
application(s):
__
shipped in:
__
storage temp.:
__
SMILES string:
CC(C)(C)S(=O)N[C@@H]1CCCC[C@H]1NC(=O)Nc2cc(cc(c2)C(F)(F)F)C(F)(F)F